Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Published 2020 View Full Article

Authors

Keywords

Gastrointestinal stromal tumour, GIST, Resistance, Imatinib, Sunitinib, Cabozantinib, KIT, MET, AXL, VEGFR

Journal

EUROPEAN JOURNAL OF CANCER

Volume 134, Issue -, Pages 62-74

Publisher

Elsevier BV

Online

2020-05-26

DOI

10.1016/j.ejca.2020.04.021

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.